Wedbush Expects Weaker Earnings for Foghorn Therapeutics

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Analysts at Wedbush dropped their Q2 2025 earnings per share estimates for Foghorn Therapeutics in a report issued on Wednesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.31) per share for the quarter, down from their previous estimate of ($0.28). The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. Wedbush also issued estimates for Foghorn Therapeutics’ Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($1.06) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $1.10 EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.30). The firm had revenue of $5.95 million for the quarter, compared to analyst estimates of $4.96 million.

A number of other research firms have also recently weighed in on FHTX. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Foghorn Therapeutics in a report on Thursday. Citigroup started coverage on Foghorn Therapeutics in a research note on Wednesday, April 23rd. They issued an “outperform” rating for the company. Citizens Jmp started coverage on Foghorn Therapeutics in a research note on Wednesday, April 23rd. They issued a “mkt outperform” rating and a $9.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Foghorn Therapeutics in a research note on Wednesday, April 30th. Finally, B. Riley started coverage on Foghorn Therapeutics in a research note on Thursday, January 30th. They issued a “buy” rating and a $10.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $12.13.

Foghorn Therapeutics Stock Up 2.8%

NASDAQ FHTX opened at $4.43 on Monday. Foghorn Therapeutics has a fifty-two week low of $2.94 and a fifty-two week high of $10.25. The stock has a market cap of $246.84 million, a price-to-earnings ratio of -2.31 and a beta of 3.13. The business has a fifty day moving average of $3.98 and a 200-day moving average of $5.14.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. boosted its holdings in Foghorn Therapeutics by 8.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 241,816 shares of the company’s stock valued at $883,000 after purchasing an additional 18,036 shares during the last quarter. AQR Capital Management LLC purchased a new position in Foghorn Therapeutics in the first quarter valued at about $68,000. DAFNA Capital Management LLC boosted its holdings in Foghorn Therapeutics by 63.2% in the first quarter. DAFNA Capital Management LLC now owns 304,752 shares of the company’s stock valued at $1,112,000 after purchasing an additional 118,035 shares during the last quarter. Wellington Management Group LLP raised its stake in Foghorn Therapeutics by 18.2% during the first quarter. Wellington Management Group LLP now owns 102,888 shares of the company’s stock valued at $376,000 after buying an additional 15,819 shares in the last quarter. Finally, Raymond James Financial Inc. raised its stake in Foghorn Therapeutics by 9.3% during the first quarter. Raymond James Financial Inc. now owns 2,218,352 shares of the company’s stock valued at $8,097,000 after buying an additional 188,969 shares in the last quarter. Hedge funds and other institutional investors own 61.55% of the company’s stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.